Campuses

As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.

Discover >

Advantages

Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.

Discover >

Genopole’s citizens

Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.

Discover >

Highlights

Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.

Discover >

Innovate with us

Discover >
Highlights

Signs of myopathy detected before muscle formation


An I-Stem team has revealed very early embryonic molecular signs of Duchenne muscular dystrophy occurring upstream of muscle development itself
muscle fiber muscle fiber

Virginie Mournetas* and the Muscular Diseases team headed by Christian Pinset at I-Stem (Inserm UMR 861, AFM-Téléthon) have shown that molecular dysregulations associated with Duchenne muscular dystrophy appear during embryonic development before muscle tissues even start to develop. The combination of an in vitro cellular model of muscle formation created from pluripotent stem cells and a multiomic approach enabled this discovery.

Duchenne muscular dystrophy (DMD) is a rare genetic disease occurring in roughly 1 out of 5000 male births and causing progressive muscle degeneration. The disease is usually diagnosed around the age of four, when muscle damage has already become significant. The efficacy of certain treatments may be hampered by this belated diagnosis, which is particularly regrettable given that current findings, some born of research at I-Stem, suggest that the disease may appear before birth. Indeed, one of the laboratory’s objectives is to better identify the moment at which the disease begins to manifest.

 

The I-Stem Muscular Diseases team designed an original study on DMD onset involving a protocol to guide iPS cell differentiation toward the muscle cell phenotype. Their protocol faithfully reproduced the key steps in myogenesis, (i.e., the formation of skeletal muscle during embryonic development): first the formation of the mesoderm, then the somites (an intermediate structure) and through to the development of myotubes (see photo), a precursor to muscle fibers. They used the protocol on iPS cells derived from either healthy people or diseased patients. Multiomics analyses (transcriptomics, microRNA, proteomics) were done at five time intervals during the 25 days of myotube differentiation to determine molecular activity in the healthy or pathological cells.

 

As early as the somite stage, 10% of the pathological transcriptomes (indicating the genes expressed by the cells) showed dysregulations compared to the healthy transcriptomes. Notably, those dysregulations concerned mitochondrial genes, known for their role in DMD.

 

This unprecedented study demonstrating a very early manifestation of DMD during embryonic development and even upstream of muscle formation itself suggests a need for a reappraisal of the disease’s natural history. Particularly, the defective dystrophin protein, which is highly deleterious to muscle fibers and the cause of DMD, could also have other effects. This aspect merits exploration as it may explain some non-muscular DMD symptoms. Toward that goal, all of the study’s analyses have been grouped in a database available to the scientific community.

  • Virginie Mournetas

    Virginie Mournetas had benefitted from a Fondagen/Genopole research grant for an initial postdoctoral project at I-Stem. That project preceded several others, including the one described here.

  • Induced Pluripotent Stem (iPS)

    Induced Pluripotent Stem (iPS) cells are created by collecting differentiated cells, those of the skin for example, and genetically reprogramming them back to the pluripotent state.

References

Journal of Cachexia, Sarcopenia and Muscle (2021)

Myogenesis modelled by human pluripotent stem cells: a multi‐omic study of Duchenne myopathy early onset. .
doi : 10.1002/jcsm.12665

Database

Designed by the research team, to access this link: https://muscle-dmd.omics.ovh/

Article posted on 10 June 2021

Share
Highlights

Latest news


Journée Croda - table ronde intitulée « Essais cliniques phases 1 et 2 : comment surmonter les obstacles réglementaires et financiers ? » Nov. 2024

Genopole and Croda Pharma ally for the Biopharma Innovation Summit

Genopole partnered with Croda Pharma to organize the Biopharma Innovation Summit, a day-long scientific event dedicated to biopharmaceutical innovation.

Discover
Ibisc - Genopole's Laboratory

Optimizing the vital debriefing step in virtual reality training

The IBISC laboratory has developed an immersive debriefing module for virtual reality training and demonstrated its ability to optimize the vital debriefing step in that setting.

Discover
Genopole Partnering Week 2024 - un format hybride au service des biotechs

Partnering Week 2024: a hybrid edition for biotech innovation

Discover the highlights of Genopole Partnering Week 2024 (#GPW2024): a hybrid event bringing together start-ups, investors, and industry leaders to accelerate biotech innovation in health and the environment.

Discover
L'équipe de la Biofonderie de Paris dont Genopole est membre au GBA 2024 en Corée

Genopole’s actions for synthetic biology and the bioeconomy

Genopole strengthens its key roles in synthetic biology, biomanufacturing and the bioeconomy, as demonstrates its notable actions carried out this fall on several national and international scenes.

Discover
Mission Bio Japan 2024 : Abolis Biotechnologies et Ispiron, accompagnées par Laurence Lacroix-Orio, directrice du Pôle Croissance et Prospection de Genopole, Paul Caroën, Program Manager et Alexis Biton, coordinateur des affaires internationales

Genopole’s mission to Japan – a country looking to lead in bioindustry

Genopole's mission to Japan was a great opportunity to extend its international network of investors and corporations in Eastern Asia. It is opening itself to partnerships with foreign start-ups to strengthen the commercial deployment of innovative breakthroughs for regenerative medicine, gene editing and artificial intelligence.

Discover
Les projets immobilier du biocluster Genopole - Evry

Real estate at Genopole: supporting growth through a strategic offer for workspace

With more than 41,000 m² of office and lab premises & more than seven hectares of available land tracts, the real estate offer of the Genopole biocluster is actively laying the groundwork for future developments with projects such as GenoLife and Cube.

Discover
Généthon - Vers une nouvelle génération de vecteurs viraux AAV pour la thérapie généique

The road toward a new generation of gene therapy vectors

Using an AI approach, Genethon has conceived a next-generation vector improving the specificity and safety of gene therapies for muscular dystrophies.

Discover

Protopia: Genopole steps into a new era of prototyping

Protopia, a new, advanced prototyping platform aimed at transforming R&D in biotech sectors, will be a resounding next-step in support for innovative biotech start-ups and businesses. It aims to accelerate project upscaling and preindustrialization while also empowering interdisciplinary partnerships.

Discover
Equipe du laboratoire LBEPS

LBEPS : Athletic performance is also forged in the laboratory

Research performed at LBEPS has resulted in three publications illustrating how a scientific approach to exercise can optimize athletic performance and health.

Discover
Laboratoire de R&D - Abolis - campus Genopole

Abolis raises €35 million from an international consortium

Abolis has reached another milestone in its upscaling objectives. Convinced by the pertinence and robustness of its technology, an international consortium of industrials and funders will provide €35 million to the company.

Discover
Hélène Virasith, Program manager à Genopole, a accompagné trois startups génopolitaines Nutropy, AuraLIP et Onima au salon Futur Food Tech de Chicago - Juin 2024

Genopole at the Future FoodTech 2024 – Chicago

Genopole was in Chicago on June 17 and 18 for the Future Food Tech conference. Genopole® accompanied three of the biocluster's companies developing more sustainable food: Nutropy, AuraLIP and Onima. This was an opportunity for them to get noticed by major US groups and investors, and to gain an insight into North American market trends.

Discover
La délégation Genopole à BIO USA 2024

Genopole at BIO International 2024

The Genopole team at the BIO International Convention in San Diego pursued three main objectives: promote Genopole accompaniment to attract new talent, highlight biocluster companies and gather information on market and regulatory tendencies.

Discover
ACS Publication - Cover May 2024 - qui contient la publication du Lambe sur les nanopores

Lambe: A new milestone on the path to nanopore-based precision diagnostics

June 2024- Lambe has demonstrated the ability of an aerolysin nanopore to discriminate enantiomeric forms of peptide biomarkers useful for medical diagnostics.

Discover
Visite de la délégation

Genopole and the Netherlands: together to accelerate the development of alternative proteins

Genopole welcomed a Dutch delegation of close to 20 company representatives and alternative proteins researchers. The objective of the visit was to explore possibilities for research and business partnerships aimed at the development of new foods capable of meeting the future's nutritional, environmental, health, business and gustatory demands.

Discover
Adnam Imeri et Jennifer Allouche, lauréats du programme financier ATIGE, créent leur équipe de recherche à Genopole respectivement en génomique et en biothérapies.

Two new research teams working on important subjects in genomics and innovative biotherapies

With its two new Atige laureates, Adnam Imeri and Jennifer Allouche, lauréats du programme financier ATIGE, create their research teams working on important subjects in genomics and innovative biotherapies.

Discover
le programme national d’envergure PEPR Biothérapies et Bioproduction,  co-piloté par Cécile Martinat, est piloté par le CEA et l'Inserm

Four biocluster labs involved in the PEPR national program

Launched in late 2023 as part of the France 2030 plan, the PEPR "Biotherapies and Biomanufacturing" program seeks to place France as the spearhead of the key sector of biodrugs. Three of the program's priority projects are headed by Genopole laboratories.

Discover
©Lionel Antoni - Plateforme d'irradiation expérimentale du LRGK - Plateforme génopolitaine mutualisée avec les acteurs de la communauté scientifique francilienne

The Experimental Irradiation Platform to serve the Île-de-France scientific community

Genopole is making available to the Île-de-France scientific community an Experimental Irradiation Platform equipped with a state of the art generator

Discover
Laina Freyer directrice scientifique, Felome

Felome Launches the Commercialization of Genetic Analyses for Companion Cats

Felome will begin the commercialization of a service offering genetic analyses for companion cats, to reveal their predispositions to over 50 diseases, identify their main physical traits, and their similarities with 14 types of breeds.

Discover
Lauréats de la promo 3 du programme Gene.iO - Genopole

Three Gene.iO whiz kids rewarded for their innovations

Three Gene.iO whiz kids, Alga Biologics, Fungu'it and Alt Biotech, rewarded for their innovations. Alga Biologics was among the 35 start-ups included in the French Blue Tech Index. Fungu'it and Alt Biotech, were selected to participate in 212 Founders, a start-up accompaniment and financing program by CDG Invest.

Discover
l'équipe iGEM 2023 Evry Paris-Saclay - Médaille d'or et p

A prize and gold for the 2023 Évry Paris-Saclay iGEM team

The international synthetic biology competition iGEM celebrated its 20th anniversary. From across the globe, the event drew more than 7,000 students in 400 teams from 66 countries. Genopole was there, among other actors in synthetic biology, to present the biocluster's advantages at its stand, and support the 17 students of the Évry Paris-Saclay team and their outstanding project, OptoGenEYEsis.

Discover
View all >
With the support from
Région île de France